Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 8/20 | 1.00 |
| ▸ | CXCR2 | P25025 | 9/20 | 0.76 |
| ▸ | CX3CR1 | P49238 | 9/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6869012 | 0.87 | PAK4 (0.77) | PAK4CXCR2CX3CR1 | |
| SCHEMBL5236487 | 0.85 | PAK4 (0.74) | PAK4CXCR2CX3CR1 | |
| SCHEMBL6865600 | 0.82 | PAK4 (0.69) | PAK4CXCR2CX3CR1 | |
| SCHEMBL6864829 | 0.81 | PAK4 (0.68) | PAK4CXCR2CX3CR1 | |
| SCHEMBL841652 | 0.78 | CXCR2 (0.65) | PAK4CXCR2CX3CR1 | |
| SCHEMBL6864817 | 0.78 | PAK4 (0.63) | PAK4CXCR2CX3CR1 | |
| SCHEMBL6859495 | 0.78 | PAK4 (0.63) | PAK4CXCR2CX3CR1 | |
| SCHEMBL28853540 | 0.78 | RAB9A (0.64) | PAK4CXCR2 | |
| SCHEMBL6868984 | 0.78 | PAK4 (0.63) | PAK4CXCR2CX3CR1 | |
| SCHEMBL6868929 | 0.77 | PAK4 (1.00) | PAK4CXCR2CX3CR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180222922-A1 | RADIOFLUORINATED 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES FOR IMAGING FRACTALKINE RECEPTOR (CX3CR1) | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-08-09 | — | — | US | disclosed |
| US-20180222922-A1 | RADIOFLUORINATED 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES FOR IMAGING FRACTALKINE RECEPTOR (CX3CR1) | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-08-09 | — | — | US | disclosed |
| WO-2016200939-A1 | RADIOFLUORINATED 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES FOR IMAGING FRACTALKINE RECEPTOR (CX3CR1) | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-12-15 | — | — | WO | disclosed |
| US-9440992-B2 | 5,7-disubstituted thiazolo[4,5-D]pyrimidines as chemokine inhibitors | Acturum Life Science AB (SE) | 2016-09-13 | — | — | US | disclosed |
| US-8158785-B2 | 5,7-disubstituted[1.3]thiazolo [4,5-D] pyrimidin-2(3H)-amine derivatives and their use in therapy | ASTRAZENECA AB (SE) | 2012-04-17 | — | — | US | disclosed |
| US-8143261-B2 | Thiazolo (4,5-D) pyrimidine compounds | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-8088780-B2 | 5,7-disubstituted thiazolo[4,5-D]pyrimidines for the selective inhibition of chemokine receptors | ASTRAZENECA AB (SE) | 2012-01-03 | — | — | US | disclosed |
| EP-2069364-B1 | NOVEL 5, 7-DISUBSTITUTED [1, 3]THIAZOLO [4, 5-D]PYRIMIDIN-2 (3H)-ONE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2011-12-14 | — | — | EP | disclosed |
| US-7960395-B2 | 5,7-disubstituted thiazolo[4,5-d]pyrimidines for the selective inhibition of chemokine receptors | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
| US-7947693-B2 | 2R)-2-[(2-amino-5-{[(1S)-1-(2-fluorophenyl)ethyl]thio}[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]pentan-1-ol; neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases su COPD, asthma | ASTRAZENECA AB (SE) | 2011-05-24 | — | — | US | disclosed |
| EP-1257556-B1 | THIAZOLOPYRIMIDINES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2004-06-16 | — | — | EP | disclosed |
| US-20040106628-A1 | Novel use | ASTRAZENECA AB (SE) | 2004-06-03 | — | — | US | disclosed |
| EP-1222195-B1 | NOVEL THIAZOLO(4,5-D)PYRIMIDINE COMPOUNDS | ASTRAZENECA UK LTD (GB) | 2004-01-14 | — | — | EP | disclosed |
| EP-1377590-A1 | THIAZOLOPYRIMIDINE DERIVATIVES AND USE THEREOF AS ANTAGONISTS OF THE CX3 CR1 RECEPTOR | AstraZeneca AB (SE) | 2004-01-07 | — | — | EP | disclosed |
| EP-1348709-A2 | Thiazolo (4,5-D) pyrimidine compounds | AstraZeneca UK Limited (GB) | 2003-10-01 | — | — | EP | disclosed |
| US-20030032642-A1 | Thiazolopyrimidines and thier use as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2003-02-13 | — | — | US | disclosed |
| EP-1104425-B1 | NOVEL THIAZOLOPYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-01-29 | — | — | EP | disclosed |
| WO-2002076990-A1 | THIAZOLOPYRIMIDINE DERIVATIVES AND USE THEREOF AS ANTAGONISTS OF THE CX3 CR1 RECEPTOR | ASTRAZENECA AB (SE) | 2002-10-03 | — | — | WO | disclosed |
| EP-1104425-A1 | NOVEL THIAZOLOPYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2001-06-06 | — | — | EP | disclosed |
| WO-2000009511-A1 | NOVEL THIAZOLOPYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222922-A1 | RADIOFLUORINATED 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES FOR IMAGING FRACTALKINE RECEPTOR (CX3CR1) | CX3CR1, CXCR3, CXCR5 | PAK4 1458/4885CXCR2 15/4885CX3CR1 1/4885 |
| US-20030032642-A1 | Thiazolopyrimidines and thier use as modulators of chemokine receptor activity | CCR5, CCR2, CXCR4 | PAK4 359/4885CXCR2 5/4885CX3CR1 9/4885 |
| US-20040106628-A1 | Novel use | CX3CR1, CNR1, ARRB1 | PAK4 3711/4885CXCR2 24/4885CX3CR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.